K21.9 R12
Conditions
Interventions
Group 1: During the observation timeframe of 14 days, patients should take the given Gaviscon sachets (as described in the package leaflet). Patients are asked to document their daily intake. The pret
Sponsors
Diakonie-Klinikum Jung-Stilling-Krankenhaus
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: - Patient suffering from GERD (gastroesophageal reflux diseas) (>1 year) - Permanent on PPI (Proton Pump Inhibitors) therapy. - Symptoms in the previous week for at least 2 days ( heartburn, regurgitation) - Dissatisfaction of the current therapy (score 1 or 2 in a scale from 1 (very dissatisfied) up to 5 (very satisfied)
Exclusion criteria
Exclusion criteria: - Patient, who do not comply with the inclusion criteria - Patients under the age of 18 year. - Patients who take antacid or other reflux medication beside the PPI standard therapy - Hypersensitivity against the active ingredient or one of the other components - Patients with hypercalcemia, nephrocalcinosis and repetitive calcium containing kidney stones - Patients with impaired renal function/ serious renal insufficiency - Patients with hypophosphatemia - Missing consent form
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary endpoint is the satisfaction after 2 week (final visit) 2 adjusted to the inclusion visit on Day 0. | — |
Secondary
| Measure | Time frame |
|---|---|
| Documentation of the disease parameter including: - Symptoms in week 2 - Satisfaction of the patient with the therapy (PPI+Gaviscon dual) - Assessment of the therapy: a) by the patient b) by the investigator | — |
Countries
Germany
Contacts
Public ContactJoachim Labenz
Diakonie-Klinikum Jung-Stilling-Krankenhaus
Outcome results
None listed